骨髓增生异常综合征最新研究进展：第56届美国血液学会年会报道

Recent progress of myelodysplastic syndrome： reports from the 56th American Society of Hematology annual meeting

骨髓增生异常综合征（MDS）是一组起源于造血干／祖细胞水平损伤而产生的获得性克隆性疾病，以无效造血和易转化为急性白血病为特点。第56届美国血液学会（ASH）年会报道了大量MDS的相关发病机制及对患者预后、指导用药意义的研究，并就不同MDS的药物治疗及造血干细胞移植等方面做了详尽报道。

The myelodysplastic syndromes （MDS）, which are characterized by the presence of ineffective hematopoiesis and an increased risk of transformation to acute myeloid leukemia （AML）, are a group of clonal disorders deriving from damage of the hematopoietic stem/progenitor cells. In the 56th American Society of Hematology （ASH） annual meeting, lots of new discoveries about the pathogenesis of MDS and the role of the pathogenesis in the clinical outcomes and treatment were introduced. There were also many developments in the treatment of MDS including drug therapies and Hematopoietic stem cell tranplantation （HSCT） reported in the meeting.